Cravings
Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial
The 3W’s and an H.
Fact Sheet.
Journal Article.
-
People with prescription-type opioid use disorder who participated in the OPTIMA trial and were randomly assigned to:
Buprenorphine/ naloxone model of care with take home doses or;
Standard model of care with closely supervised methadone
-
To compare the effectiveness of flexible BUP/NX model of care to methadone for reducing cravings in individuals with prescription-type opioid use disorder.
-
Cravings was measured using the Brief Substance Craving Scale at baseline, week 2, 6, 10, 14, 18 and 22.
-
Cravings decreased in both treatment groups over 22 weeks.
Cravings were overall lower in the flexible BUP/NAL group vs. the methadone group.